# Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis

Source: https://onco.cc/trials/nct07545213/  
OnCo record `nct07545213` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab tirumotecan in lung cancer, run by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, not yet recruiting.

## Summary

Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis is a phase 2, interventional study registered as NCT07545213 by The Fourth Affiliated Hospital of Zhejiang University School of Medicine, with a registry enrolment figure of 27 participants, started 2026-04-20 and due to reach its primary completion in 2028-02-15. Interventions recorded: SKB264. Conditions listed: Non-small Cell Lung Cancer; EGFR Mutant Advanced Non-small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: "Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) that is locally advanced (stage IIIB/IIIC) or metastatic (stage IV) and not amenable to curative surgery and/or curative radiotherapy (with or without concurrent chemotherapy), according to the IASLC 9th edition lung cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07545213
- Phase: 2
- Setting: Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistant Advanced NSCLC With Liver Metastasis
- Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Enrolled: 27

## Sources

- ClinicalTrials.gov NCT07545213: https://clinicaltrials.gov/study/NCT07545213

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07545213.json